-
公开(公告)号：US20220118073A9
公开(公告)日：2022-04-21
申请号：US17155592
申请日：2021-01-22
Applicant: ModernaTX, Inc.
Inventor： Giuseppe Ciaramella , Sunny Himansu , Vladimir Presnyak , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K39/12 , A61P31/14 , A61K31/7115 , C12N15/86
Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
-
公开(公告)号：US20220071915A1
公开(公告)日：2022-03-10
申请号：US17154325
申请日：2021-01-21
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Stephen Hoge , Kerry Benenato , Vladimir Presnyak , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Jingsong Cao , Lin Tung Guey , Staci Sabnis
Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.
-
公开(公告)号：US20210252129A1
公开(公告)日：2021-08-19
申请号：US17155592
申请日：2021-01-22
Applicant: ModernaTX, Inc.
Inventor： Giuseppe Ciaramella , Sunny Himansu , Vladimir Presnyak , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K39/12 , A61P31/14 , A61K31/7115 , C12N15/86
Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
-
公开(公告)号：US10993918B2
公开(公告)日：2021-05-04
申请号：US16302360
申请日：2017-05-18
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Stephen Hoge , Kerry Benenato , Vladimir Presnyak , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Jingsong Cao , Lin Tung Guey , Staci Sabnis
Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.
-
公开(公告)号：US10519455B2
公开(公告)日：2019-12-31
申请号：US16110309
申请日：2018-08-23
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Stephen G. Hoge , Kerry Benenato , Vladimir Presnyak , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Xuling Zhu , Lin Tung Guey , Staci Sabnis
Abstract: The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
-
Patent Agency Ranking
公开(公告)号：US10335486B2
公开(公告)日：2019-07-02
申请号：US15996146
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Susannah Hewitt , Ailin Bai , Stephen G. Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K39/39 , A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K45/06 , A61K31/713 , A61K39/00 , A61P35/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US12239742B2
公开(公告)日：2025-03-04
申请号：US17154325
申请日：2021-01-21
Applicant: ModernaTX, Inc.
Inventor： Paolo Martini , Stephen Hoge , Kerry Benenato , Vladimir Presnyak , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Jingsong Cao , Lin Tung Guey , Staci Sabnis
Abstract: The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.
-
公开(公告)号：US12151995B2
公开(公告)日：2024-11-26
申请号：US18467190
申请日：2023-09-14
Applicant: ModernaTX, Inc.
IPC: C07C229/12 , A61K9/00 , A61K9/127 , A61K9/16 , A61K9/51 , A61K31/7105 , A61K38/17 , A61K38/18 , A61K47/54 , A61K47/69 , A61K48/00 , C07C227/16 , C07C227/18 , C07C229/16 , C07C233/36 , C07C233/72 , C07C235/10 , C07C255/24 , C07C263/20 , C07C271/20 , C07C275/14 , C07C279/12 , C07C279/24 , C07C279/28 , C07C279/32 , C07C311/05 , C07C335/08 , C07D207/27 , C07D233/72 , C07D249/04 , C07D263/20 , C07D265/33 , C07D271/06 , C07D271/10 , C07D277/38 , C07F9/09 , C07K14/505
Abstract: The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
-
公开(公告)号：US11801227B2
公开(公告)日：2023-10-31
申请号：US16302370
申请日：2017-05-18
Applicant: ModernaTX, Inc.
Inventor： Kerry Benenato , Stephen Hoge , Iain McFadyen , Vladimir Presnyak , Paolo Martini , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K38/18 , A61K9/51 , A61K9/00 , A61K9/127 , C07K14/705 , C07K14/47 , A61P11/00 , A61K38/17 , C12N15/88
CPC classification number: A61K9/5123 , A61K9/0043 , A61K9/0053 , A61K9/0073 , A61K38/177 , A61P11/00 , C07K14/47 , C12N15/88 , A61K9/1271
Abstract: The invention relates to mRNA therapy for the treatment of cystic fibrosis. mRNAs for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR), isoforms thereof, functional fragments thereof, and fusion proteins comprising CFTR. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of CFTR expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient CFTR activity in subjects.
-
公开(公告)号：US11596609B2
公开(公告)日：2023-03-07
申请号：US17930369
申请日：2022-09-07
Applicant: ModernaTX, Inc.
Inventor： Joshua Frederick , Ailin Bai , Vladimir Presnyak , Stephen Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K9/51 , A61K48/00 , A61K38/17 , A61K38/20 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
-
-
-
-
-
-
-
-
Search Results
50
records
(took 0.068 seconds)
